JP2016537408A - 非晶質マグネシウム置換リン酸カルシウム組成物及びその使用 - Google Patents

非晶質マグネシウム置換リン酸カルシウム組成物及びその使用 Download PDF

Info

Publication number
JP2016537408A
JP2016537408A JP2016551077A JP2016551077A JP2016537408A JP 2016537408 A JP2016537408 A JP 2016537408A JP 2016551077 A JP2016551077 A JP 2016551077A JP 2016551077 A JP2016551077 A JP 2016551077A JP 2016537408 A JP2016537408 A JP 2016537408A
Authority
JP
Japan
Prior art keywords
composition
treatment
calcium phosphate
cargo
amorphous magnesium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016551077A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016537408A5 (https=
Inventor
パウエル，ジョナサン・ジョセフ
ファリア，ヌーノ・ジョルジ・ロドリゲス
ペレ，ラエティティア
ヒューイット，レイチェル
トーマス−マッケイ，エマ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Publication of JP2016537408A publication Critical patent/JP2016537408A/ja
Publication of JP2016537408A5 publication Critical patent/JP2016537408A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B25/00—Phosphorus; Compounds thereof
    • C01B25/16—Oxyacids of phosphorus; Salts thereof
    • C01B25/26—Phosphates
    • C01B25/32—Phosphates of magnesium, calcium, strontium, or barium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/587—Nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Optics & Photonics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
JP2016551077A 2013-11-05 2014-11-05 非晶質マグネシウム置換リン酸カルシウム組成物及びその使用 Pending JP2016537408A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1319548.2 2013-11-05
GBGB1319548.2A GB201319548D0 (en) 2013-11-05 2013-11-05 Amorphous magnesium-substituted calcium phosphate compositions and their uses
PCT/GB2014/053291 WO2015067939A1 (en) 2013-11-05 2014-11-05 Amorphous magnesium-substituted calcium phosphate compositions and their uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019173127A Division JP2020073467A (ja) 2013-11-05 2019-09-24 非晶質マグネシウム置換リン酸カルシウム組成物及びその使用

Publications (2)

Publication Number Publication Date
JP2016537408A true JP2016537408A (ja) 2016-12-01
JP2016537408A5 JP2016537408A5 (https=) 2017-11-02

Family

ID=49767709

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016551077A Pending JP2016537408A (ja) 2013-11-05 2014-11-05 非晶質マグネシウム置換リン酸カルシウム組成物及びその使用
JP2019173127A Withdrawn JP2020073467A (ja) 2013-11-05 2019-09-24 非晶質マグネシウム置換リン酸カルシウム組成物及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019173127A Withdrawn JP2020073467A (ja) 2013-11-05 2019-09-24 非晶質マグネシウム置換リン酸カルシウム組成物及びその使用

Country Status (16)

Country Link
US (1) US10596122B2 (https=)
EP (1) EP3065715B1 (https=)
JP (2) JP2016537408A (https=)
KR (1) KR20160079060A (https=)
CN (1) CN105722504A (https=)
AU (1) AU2014345334B2 (https=)
BR (1) BR112016009809A2 (https=)
CA (1) CA2929123A1 (https=)
EA (1) EA201690659A1 (https=)
ES (1) ES2761559T3 (https=)
GB (1) GB201319548D0 (https=)
IL (1) IL245380B (https=)
MX (1) MX367473B (https=)
SG (2) SG10201803562YA (https=)
WO (1) WO2015067939A1 (https=)
ZA (1) ZA201602906B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018198296A1 (ja) * 2017-04-27 2018-11-01 ブレイニー株式会社 ハイドロキシアパタイト、化粧品及び食品、並びにその製造方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201319548D0 (en) 2013-11-05 2013-12-18 Medical Res Council Amorphous magnesium-substituted calcium phosphate compositions and their uses
FR3021045B1 (fr) * 2014-05-16 2020-02-21 Solvay Sa Procede de production d'un reactif phosphocalcique, reactif obtenu et son utilisation
KR101893110B1 (ko) * 2016-07-27 2018-08-31 삼일제약 주식회사 비페닐디메틸디카르복실레이트 및 마늘유를 포함하는 제제
EP3538659A4 (en) * 2016-11-09 2020-07-15 Engene, Inc. INTESTINAL EXPRESSION OF THE SCHEDULED DEATH LIGAND 1
CN111417459B (zh) * 2019-07-05 2020-12-29 广州中大医疗器械有限公司 一种可载药微球及其制备方法
CN114615966B (zh) 2019-10-30 2025-10-10 皮斯洛克斯有限公司 稳定的非晶态钙镁磷酸盐颗粒组合物
CN116768175B (zh) * 2023-07-01 2025-12-19 常州市第二人民医院 高稳定性生物活性无定形磷酸钙镁的制备方法及应用
CN118929595A (zh) * 2024-08-30 2024-11-12 昆明理工大学 稳定型掺镁无定形磷酸钙纳米颗粒的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04507106A (ja) * 1990-04-16 1992-12-10 プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ ヒドロキシアパタイト―抗原結合体及びポリ―ｉｇ免疫応答を生成する方法
WO2006109635A1 (ja) * 2005-04-06 2006-10-19 Kabushiki Kaisha Sangi 腸管吸収用抗腫瘍剤
JP2010512161A (ja) * 2006-12-12 2010-04-22 フイルメニツヒ ソシエテ アノニム キャリヤーとしての非晶質金属塩を有する有効成分送達系
JP2011519867A (ja) * 2008-05-01 2011-07-14 ノッド ファーマシューティカルズ， インコーポレイテッド 治療用リン酸カルシウム粒子、ならびにその作製および使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541037B1 (en) * 1995-05-19 2003-04-01 Etex Corporation Delivery vehicle
GB201319548D0 (en) 2013-11-05 2013-12-18 Medical Res Council Amorphous magnesium-substituted calcium phosphate compositions and their uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04507106A (ja) * 1990-04-16 1992-12-10 プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ ヒドロキシアパタイト―抗原結合体及びポリ―ｉｇ免疫応答を生成する方法
WO2006109635A1 (ja) * 2005-04-06 2006-10-19 Kabushiki Kaisha Sangi 腸管吸収用抗腫瘍剤
JP2010512161A (ja) * 2006-12-12 2010-04-22 フイルメニツヒ ソシエテ アノニム キャリヤーとしての非晶質金属塩を有する有効成分送達系
JP2011519867A (ja) * 2008-05-01 2011-07-14 ノッド ファーマシューティカルズ， インコーポレイテッド 治療用リン酸カルシウム粒子、ならびにその作製および使用方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ＣＬＩＮＩＣＡＬ ＩＭＭＵＮＯＬＯＧＹ, vol. 143, no. 2, JPN6018023974, 2012, pages 162 - 169, ISSN: 0004039146 *
ＧＥＮＥ, vol. 341, JPN6018023980, 2004, pages 77 - 82, ISSN: 0004039148 *
ＪＯＵＲＮＡＬ ＯＦ ＣＯＮＴＲＯＬＬＥＤ ＲＥＬＥＡＳＥ, vol. 116, no. 1, JPN6018023971, 2006, pages 1 - 27, ISSN: 0004039145 *
ＪＯＵＲＮＡＬ ＯＦ ＭＡＴＥＲＩＡＬＳ ＣＨＥＭＩＳＴＲＹ, vol. 20, no. 1, JPN6018023976, 2010, pages 18 - 23, ISSN: 0004039147 *
ＬＡＮＧＭＵＩＲ, vol. 26, no. 7, JPN6018023966, 2010, pages 4958 - 4964, ISSN: 0004039144 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018198296A1 (ja) * 2017-04-27 2018-11-01 ブレイニー株式会社 ハイドロキシアパタイト、化粧品及び食品、並びにその製造方法
JP6435061B1 (ja) * 2017-04-27 2018-12-05 ブレイニー株式会社 ハイドロキシアパタイト、化粧品及び食品、並びにその製造方法
US12201709B2 (en) 2017-04-27 2025-01-21 Brainy Inc. Hydroxyapatite, cosmetic, food, and method for producing the same

Also Published As

Publication number Publication date
JP2020073467A (ja) 2020-05-14
MX367473B (es) 2019-08-23
CA2929123A1 (en) 2015-05-14
SG11201603261PA (en) 2016-05-30
KR20160079060A (ko) 2016-07-05
MX2016005415A (es) 2017-03-01
US20160235683A1 (en) 2016-08-18
EP3065715B1 (en) 2019-10-02
EA201690659A1 (ru) 2016-10-31
IL245380B (en) 2019-02-28
WO2015067939A1 (en) 2015-05-14
AU2014345334A1 (en) 2016-05-19
ES2761559T3 (es) 2020-05-20
CN105722504A (zh) 2016-06-29
BR112016009809A2 (pt) 2017-12-05
EP3065715A1 (en) 2016-09-14
GB201319548D0 (en) 2013-12-18
ZA201602906B (en) 2019-09-25
US10596122B2 (en) 2020-03-24
AU2014345334B2 (en) 2019-10-31
IL245380A0 (en) 2016-06-30
SG10201803562YA (en) 2018-06-28

Similar Documents

Publication Publication Date Title
JP2016537408A (ja) 非晶質マグネシウム置換リン酸カルシウム組成物及びその使用
Freitag et al. Gliadin nanoparticles induce immune tolerance to gliadin in mouse models of celiac disease
JP6570082B2 (ja) 炎症を治療するための方法および組成物
RU2635537C2 (ru) Способ лечения аутоиммунного заболевания с использованием биосовместимых биоабсорбируемых наносфер
CN111265549A (zh) 表面pd-l1分子过表达的间充质干细胞膜包被的仿生纳米颗粒及其制备和应用
AU2020267191A1 (en) Polymeric bile acid nanocompositions targeting the pancreas and colon
Smith et al. Cationic nanoparticles enhance T cell tumor infiltration and antitumor immune responses to a melanoma vaccine
EP3740242B1 (en) Langerin+-cell targeting
KR20140037789A (ko) 암의 예방 및 치료를 위한 조성물 및 방법
JP2016537408A5 (https=)
Ren et al. A biomimetic, triggered‐release micelle formulation of methotrexate and celastrol controls collagen‐induced arthritis in mice
WO2025147671A1 (en) Immune cell-specific protein degraders and methods of use thereof for immunotherapy
Zhang et al. Hyaluronate-based Self-stabilized Nanoparticles for Reverting Immunosuppression and Immunochemotherapy in Osteosarcoma Treatment
Nayak et al. Chitosan micro and nanoparticles for delivery of drugs and therapeutic proteins
Conniot Multicomponente particulates for immune modulation
de Oliveira Conniot Maulticomponente Particulates for Immune Modulation
HK40020863A (en) Methods and compositions for treating inflammation
Bani Hani Effects of Carboxylated Nanodiamonds on Macrophages During and After Differentiation
Parida Natural polymer based (alginate and chitosan) Microparticles for oral drug delivery
de Jong et al. NOD2/CARD15 modulates specific Toll-like receptor pathways for the induction of cytokine release
Zelinkova et al. Functional consequences of NOD2 deficiency in Crohn's disease patients peripheral blood monocytes derived dendritic cells
BR112014023859B1 (pt) Nanopartícula, uso da mesma, e composição
HK1206641B (en) Methods and compositions for treating inflammation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170925

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170925

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180627

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181227

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20190410

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190522